The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis

Pract Neurol. 2016 Feb;16(1):4-6. doi: 10.1136/practneurol-2015-001209. Epub 2015 Oct 1.
No abstract available

Keywords: GLATIRAMER ACETATE; HEALTH ECONOMICS; INTERFERON; MULTIPLE SCLEROSIS.

Publication types

  • Editorial

MeSH terms

  • Glatiramer Acetate / therapeutic use*
  • Humans
  • Immunologic Factors / therapeutic use*
  • Interferon-beta / therapeutic use*
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / epidemiology
  • United Kingdom / epidemiology

Substances

  • Immunologic Factors
  • Glatiramer Acetate
  • Interferon-beta